A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.

Michael J. Overman, Harold M. Wright, Mariela Blum‐Murphy et al.|Journal of Clinical Oncology|2023

Cited by 18